Recurrent oropharyngeal, vaginal, and esophageal candidiaepidemiological patterns, microbiological features, therapeutic interventions, and outcomes of the 13 episodes of candidemia ses are well described as occurring in patients infected with HIV because of both functional and quantitative defects of that occurred in HIV-infected adults hospitalized in a French university hospital between 1990 and 1995. CD4 / T lymphocytes [1] . Resistance of Candida albicans strains isolated during oropharyngeal candidiasis in HIV-infected patients, especially against fluconazole, is now comPatients and Methods monly reported and sometimes occurs with cross-resistance to other azoles such as ketoconazole and itraconazole [2 -5] .
Patients
Candidemia is a common nosocomial complication in patients Between 1 July 1990 and 1 July 1995, 104 patients with hospitalized in intensive care units or those with hematologic blood cultures positive for Candida species were identified at malignancies with neutropenia [6 -13] . In the latter, episodes Avicenne Hospital (a university hospital with 650 beds, includcaused by fluconazole-resistant C. albicans have been reported ing the medical and surgical units), in Bobigny, France. Medi- [14] . Non-albicans strains also have emerged as significant cal charts of 58 adults contained sufficient epidemiological, pathogens responsible for candidemia in several series, especlinical, and follow-up information for them to be included in cially in fluconazole-treated patients [11, 14 -18] .
our study [28] . Of the 104 patients with candidemia, only 13 Disseminated fungal infections, including candidemia, were were HIV-infected and are described herein. first described as occurring in HIV-infected children [19] . More
The medical charts of these 13 patients were reviewed for recently, Walsh and co-workers [20, 21] described 22 HIVepidemiological patterns, immunologic status, possible risk facinfected children who had 27 episodes of fungemia, among tors for candidemia (including the presence of a central venous which 24 were caused by Candida species. By contrast, candicatheter [CVC]), concomitant nonfungal infections, clinical demia in HIV-infected adults has rarely been reported, mostly manifestations of candidemia, Candida species isolated, potenin isolated case reports. Candidemic episodes have most often tial risk factors for the occurrence of infection with nonbeen due to C. albicans [22 -24] , but non-albicans species albicans strains, therapeutic interventions, and outcomes. Data have also been anecdotally reported as pathogens [24 -27] .
on previous episodes of mucosal candidiasis were recorded Because no study on candidemia occurring in HIV-infected when available, and all treatments with fluconazole prior to the adults has yet been published, we undertook an analysis of the episode of candidemia were noted. Patients were classified according to the 1993 classification system of the Centers for Disease Control and Prevention (CDC) [29] . tion when they had the same Candida species in at least one (bioMérieux), used from July 1990 to December 1994, and Sabouraud/chloramphenicol and Sabouraud/chloramphenicol/acmucosal culture within 2 months before candidemia. Neutropenia was defined as an absolute neutrophil count of tidione (bioMérieux) with Isolator 10 lysis centrifugation (Wampole, Cranbury, NJ) used from January 1995 to July 1995. £500/mm 3 within 1 month of the episode of candidemia. The last CD4 cell count given was the last one available for the To determine CVC infection, the CVC was withdrawn and its tip was cut off and shaken in diphasic Sabouraud-Hemoline month preceding the onset of candidemia.
Steroid therapy was defined as the administration of corticomedium and plated at 37ЊC. C. albicans was identified through the germ-tube test. Other Candida species were identified by steroids at a dosage of §0.5 mg/(kgrd) for §8 days within 1 month before the episode of candidemia. Recent bacterial the API system: API 20C Candida and API 20C Aux (bioMér-ieux). Antifungal susceptibility testing was performed with use infection was defined as a bacterial infection diagnosed within the month preceding the episode of candidemia, and concomiof ATB Fungus (bioMérieux) from July 1990 to December 1994. Since January 1995, fluconazole and itraconazole have tant bacterial infection was defined as a bacterial infection arising during the last 48 hours before the episode of candidebeen tested by the disk method with Shadomy medium and Rosco-Neo-Sensitabs (Rosca, Taastrup, Denmark). mia. Recent surgery was defined as a surgical intervention within 1 month prior to the episode of candidemia. Previous antibiotic therapy was defined as the administration of antibiotResults ics during the month preceding the onset of candidemia, except for antibiotics prescribed prophylactically for opportunistic inDuring the 5-year study period (July 1990 through July 1995), candidemia occurred in 13 HIV-infected adults hospitalized in fections (e.g., trimethoprim-sulfamethoxazole and rifabutin). b-Lactam antibiotics with antianaerobic activity (e.g., piperatwo medical units of Avicenne Hospital (7 and 6 cases, respectively). Both units included 10 single-bed rooms assigned exclucillin/tazobactam and ticarcillin/clavulanic acid) or reported to have a high gastrointestinal concentration (e.g., cefotaxime and sively to HIV care and 20 and 13 nurses for each unit, respectively. The estimated annual incidence of candidemia (i.e., the ceftriaxone) [31] and glycopeptides [32] were analyzed separately, since they have been described as promoting the growth number of episodes of candidemia occurring during 1 year, divided by the total number of HIV-infected patients recruited in of Candida species [33] .
The development of cardiovascular, respiratory, renal, heour cohort during each annual period) for our entire cohort of HIV-infected patients was 3 per 300 HIV-infected patients (1%) patic, hematologic and/or neurological organ failure was recorded according to the organ dysfunction and/or infection between July 1990 and July 1991; it then varied between 1 per 440 HIV-infected patients (0.2%) (July 1991 through July 1992) (ODIN) model of Fagon et al. [34] . Evolutive pneumonia was defined as respiratory or radiological signs of pulmonary infecand 4 per 485 (0.8%) (July 1994 through July 1995). Among the 13 patients with candidemia, only two were intravenous drug tion. Disseminated candidiasis was primarily evaluated clinically, and three patients underwent ophthalmoscopy. For pausers (IVDUs), while 60% of the patients belonging to our cohort of HIV-infected patients were IVDUs. tients presenting with suggestive clinical features (i.e., cholestatic hepatitis or renal insufficiency), radiological examiData concerning pertinent demographic features and the immunologic status of these 13 patients are described in table 1. nations were performed.
Patients with candidemia were considered to be cured when There were nine men and four women, whose mean age was 34 years (range, 28-67 years). Except for patient 1, who had clinical or radiological signs of disseminated candidiasis were absent and follow-up blood cultures had become negative.
confirmed hepatitis B virus-related liver cirrhosis, all patients were severely immunocompromised because of HIV infection. Death was considered to be secondary to the candidemia when it was due to septic shock that was concomitant with CandidaAccording to the CDC 1993 classification, 12 patients had AIDS.
The mean CD4 / cell count was 64/mm 3 (range, 3 -400/mm 3 ). positive blood cultures.
The mean CD4/CD8 cell ratio was 0.2 (range, 0.03-0.3). Eight patients were tested for the presence of serum p24
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antigen within the month before the onset of candidemia, and five of them were positive. At the onset of candidemia, 10 When fever developed, blood was drawn for culture through the CVC and from peripheral venous sites. From July 1990 to patients were receiving antiretroviral therapy: zidovudine was administered to 9 of them for a mean of 17 months (range, 1 -36 February 1994, every blood sample was routinely inoculated into Shaedler medium and diphasic Castaneda medium (bioMérieux, months), and the last patient received lamivudine. Candidemia occurred as a nosocomially acquired infection in 11 HIV-inMarcy l'Etoile, France). From March 1994 to July 1995, blood cultures were performed with use of Bactec plus aerobic/F and fected patients who were hospitalized for §8 days (mean, 36 days; range, 8 -120 days). A CVC had been inserted into 7 of Bactec plus anaerobic/F kits (Becton-Dickinson Europe, Meylan, France). Blood specimens sent to the mycology laboratory were these 11 patients (table 1) and remained for a mean of 43 days (range, 1 -200 days); 5 (patients 4, 6, 7, 10, and 11) had a also incubated at 37ЊC for a maximum of 15 days after being inoculated into special media: diphasic Sabouraud-Hemoline Hickman catheter, and 2 (patients 8 and 13) had a Port-a-cath / 9c4c$$my26 04-10-98 01:32:24 cida UC: CID NOTE. AmB Å amphotericin B (1 mg/[kgrd]); BAL Å bronchoalveolar lavage fluid; CA Å community-acquired; CMV Å cytomegalovirus; CVC Å central venous catheter; Flu Å fluconazole; HBV Å hepatitis B virus; Het Å heterosexual; Hom Å homosexual or bisexual; IL Å intralipid administration; IVDU Å iv drug user; MAC Å Mycobacterium avium complex; ND Å not determined; Nos Å nosocomially acquired; PCP Å Pneumocystis carinii pneumonia; Periph Å peripheral site; TD Å total dose; Transf Å transfusion.
* Data are from [29] .
(Pharmacia, North Ryde, Australia). In addition, AIDS patients with cholestatic hepatitis or renal insufficiency detected no abscesses. Three patients underwent ophthalmoscopy, but no 5 and 9 had been medically treated for 34 and 45 days at home, respectively, receiving daily iv infusions of ganciclovir as supevidence of lesions suggestive of disseminated candidiasis was found. However, an autopsy was performed on one papressive therapy for cytomegalovirus retinitis through a Hickman catheter or a Port-a-cath, respectively, that had been intient with C. albicans candidemia who had had a C. albicans urinary tract infection, and histologic examination revealed serted 40 and 270 days earlier (table 1) .
The most common clinical manifestation of candidemia renal candidiasis. C. albicans was isolated from nine patients (69%), and was fever, present during all but one episode. When candidemia occurred, 11 patients had oral or esophaately susceptible. No data were available concerning the susceptibility of the C. glabrata strains to fluconazole. geal candidiasis; the four patients with non-albicans candidemia had both oral candidiasis and diarrhea. All of these organThe mean serum protein level was 64.1 g/L (range, 45 -84 g/L), and the mean serum albumin level was 29 g/L (range, isms were isolated from peripheral blood but also from blood taken through the CVCs of seven of nine patients with such 12 -38 g/L). The classic risk factors for candidemia that our patients had devices (table 1) . No cultures of CVC-drawn blood were performed for 2 patients, of whom 1 had clinical evidence of CVC are listed in table 2. Eleven patients (85%) had been treated with antibiotics (table 2) . Among them, four (31%) had reinfection and 1 had no sign of local CVC infection. All blood cultures became positive within a mean of 2 days (range, 1 -ceived broad-spectrum b-lactams with antianaerobic activity or high gastrointestinal concentration, and two (15%) were 5 days) and remained positive for a mean of 5 days after diagnosis (range, 1 -17 days).
given glycopeptides. Nine patients received parenteral nutrition at the onset of candidemia, seven of them through a CVC. Resistance to flucytosine was noted in three of the 13 Candida isolates. No fluconazole-resistant C. albicans strain was Eleven (85%) of the 13 episodes of candidemia involved 11 patients who had previously received fluconazole (mean total detected by the susceptibility testing methods described above. Of the two C. albicans strains isolated after January 1995, one dose, 7.4 g; range, 0.8 -28.5 g) for oral or esophageal candidiasis (mean duration, 108 days; range, 4 -360 days). Seven of was susceptible to fluconazole and the other one was intermedi-/ 9c4c$$my26 04-10-98 01:32:24 cida UC: CID who had no CVC, had only one positive peripheral blood culGlycopeptides 2 (15) Neutropenia* 1 (8) ture and was cured by fluconazole alone, while patient 13 was
Corticosteroid use 2 (15) cured by iv amphotericin B and CVC removal. All patients who
Active iv drug use 2 (15) received iv amphotericin B had their daily dose progressively Hypoalbuminemia † 5 (38) increased to reach 1 mg/(kgrd) on day 4. Among the nine Diabetes mellitus 0 patients with a CVC, two died rapidly after the onset of candiRecent surgery 0 Recent bacterial infection (£1 mo previously)
6 (46) demia, before the removal of their CVC. The remaining 7 Bacteremia 1 (8) CVCs were removed within 8 days: 6 were cultured and 2
Pneumonia 5 (38) were positive, both for C. albicans.
Cutaneous infection 1 (8)
After 2 months of follow-up, eight patients (62%) were alive Among the four patients with non-albicans candidemia, 1 (25%) died on day 6 with persistent C. glabrata candidemia.
these 11 episodes were caused by C. albicans (mean total dose [17, 39] . In a recent study, the frequency of candidemia due to nonMucosal candidiasis is the most common opportunistic infecalbicans species increased significantly throughout the 3.5-tion in patients with AIDS. It occurs in up to 90% of them at year study period, from 40% to 53% of all candidemic episome time during the course of their disease [35] . Candidemia sodes [40] . Similarly, among other patients hospitalized in has rarely been described as occurring in HIV-infected adults our institution during the study period, the frequency of candiand has mostly been reported as single cases [22 -27] . Howdemia due to non-albicans species was 52%, including ever, one study noted that between 1985 and 1989 there was C. tropicalis and C. parapsilosis, 16% each; C. glabrata, a 10-fold increase in the rate of disseminated candidiasis in 9%; and C. krusei, 5% [28] . More frequent isolation of non-HIV-infected patients (from 9 1 10 05 to 0.02 case per 1,000 albicans species from the oral cavity of HIV-positive patients, admissions by 1989) [36] . Furthermore, 14 cases of candidal especially those treated with fluconazole, has also been remeningitis in HIV-infected adults were analyzed in a recent ported [41 -43] . However, the pathogenicity of these species study [37] . In addition, two series of patients with fungemia remains controversial [44] . were described from among pediatric HIV-infected populaIn our study, C. albicans was the principal Candida species tions, including 9 of 156 children at New York University and causing candidemia. We found that 54% of our patients had Bellevue Hospital Centers [19] and 27 episodes involving 22 previously harbored the same Candida species in mucosal samof 347 children at the National Institutes of Health [20] .
ples. It is pertinent to note that for the four patients who develIn our active cohort of HIV-infected adults, the annual incioped candidemia due to non-albicans species (C. glabrata and dence remained low, varying between 0.2% and 1%. Whimbey C. krusei in two cases each), we documented previous gastroinet al. reported similar results, with an incidence of 1% among testinal tract colonization by the same species within the 2 their HIV-infected patients [22] . However, although no definimonths prior to the candidemic episode, a finding that has been tive conclusions can be drawn from our study, we observed reported for other high-risk populations [39] . A prospective that among the patients who developed nosocomial candidemia study should be performed to further assess the relationship in our hospital, a high proportion (13 of 104, or 13%) were between gastrointestinal tract colonization and disseminated HIV infected.
candidiasis in hospitalized patients with late-stage AIDS. In a recent case-control study, risk factors affecting the oc-
The association of breakthrough candidemia with non-albicurrence of fungemia in HIV-infected children were the prescans species during antifungal therapy has previously been ence of a CVC, CVC placement for ú90 days, treatment with observed [40] , particularly C. krusei candidemia during flucomore than three parenteral antibiotics, duration of antibiotic nazole prophylaxis [17, 45] . In a recently reported retrospective therapy of ú30 days, an absolute CD4
/ cell count of study [46] involving cancer patients, fluconazole was the single õ100/mm to demonstrate that prior systemic antifungal azole compounds The results of our study indicated that candidemia occurred in had an effect on the species causing the present episode of patients with advanced HIV infection (median CD4 / cell count, fungemia [20] . In our study, about 85% of the episodes of 10/mm 3 ; late-stage AIDS in all cases except one). All but one candidemia involved patients who had previously received fluof our patients had recently received broad-spectrum antibiotic conazole for mucosal candidiasis. It is surprising that the mean therapy, and 70% of them had a CVC inserted for parenteral total dose of fluconazole was higher among patients with nutrition. Only two patients were active IVDUs, and one patient C. albicans candidemia than among those with non-albicans was neutropenic (170/mm 3 ) at the onset of candidemia. Candidecandidemia. However, all four patients who developed nonmia in our HIV-infected adults presented as a nosocomial infection albicans candidemia were being treated with fluconazole for in 11 patients, and two episodes involved home-care patients who mucositis or esophagitis at the onset of the candidemia, as were received ganciclovir through a CVC. Thus, alternatives to classic three patients who developed C. albicans candidemia. hospitalization may be beneficial to severely immunocomproTherefore, candidemia occurring in HIV-infected patients mised HIV-infected patients, provided that invasive procedures treated with fluconazole, especially in those with previously are carefully monitored.
documented colonization, should lead to the suspicion of a Since the last decade, an important change in the epidemiolnon-albicans species. For HIV-infected patients previously cology of opportunistic and nosocomial candidal infections has onized with non-albicans species, amphotericin B should probbeen the emergence of non-albicans species, mostly in populaably be prescribed as first-line antifungal therapy when a blood tions with hematologic malignancies [38] . In HIV-negative culture is positive for yeast. neutropenic patients with candidemia, the prevalence of Similarly, the emergence of fluconazole-resistant C. albicans during fluconazole prophylaxis has previously been reported C. albicans infections has decreased, and non-albicans species / 9c4c$$my26 04-10-98 01:32:24 cida UC: CID
